JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266776

Human FANCG knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

FANCG KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 10 bp deletion in exon 3.

View Alternative Names

DNA repair protein XRCC9, FAG, FANCG_HUMAN, Fanconi anaemia complementation group G, Fanconi anemia group G protein, Protein FACG, X ray repair, complementing defective, in Chinese hamster cells 9, X-ray repair, complementing defective, in Chinese hamster, 9, XRCC9

1 Images
Sanger Sequencing - Human FANCG knockout HEK-293T cell line (AB266776)
  • Sanger seq

Unknown

Sanger Sequencing - Human FANCG knockout HEK-293T cell line (AB266776)

Homozygous : 10 bp deletion in exon3

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 10 bp deletion in exon 3

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266776-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266776 Human FANCG knockout HEK-293T cell line", "number":"AB266776-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266776-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266776 Human FANCG knockout HEK-293T cell line", "number":"AB266776-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
FANCG
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

FANCG also known as Protein FACG or Fanconi anemia group G protein is a component involved in DNA repair. It has a mass of approximately 68 kDa. This protein is mainly expressed in tissues with high proliferative rates such as bone marrow and germ cells. Mechanically FANCG plays an important role in the maintenance of genomic stability by participating in the repair processes that fix DNA interstrand crosslinks.
Biological function summary

Fanconi anemia group G protein is an essential part of the Fanconi anemia (FA) core complex which consists of several FA proteins. This complex is indispensable for cellular resistance to DNA damage as it repairs broken DNA strands and stalls replication forks. FANCG as part of this multiprotein complex ensures proper cellular responses to genotoxic stresses and helps in preventing mutations that could be passed to daughter cells.

Pathways

FANCG primarily functions within the FA/BRCA pathway an essential mechanism for DNA damage response and repair. It interacts closely with other FA proteins such as FANCA and FANCJ to facilitate the monoubiquitination of the FANCD2-FANCI complex a critical step in the DNA damage repair. Additionally the FA pathway is linked to homologous recombination repair where FANCG indirectly associates with BRCA1 and BRCA2 proteins coordinating with them to maintain genomic integrity.

Defects in FANCG are directly associated with Fanconi anemia a rare genetic disorder characterized by bone marrow failure and increased cancer susceptibility. FANCG mutations disrupt its interaction within the FA complex leading to increased cellular susceptibility to DNA damage. Moreover alterations in FA pathway components including FANCG also relate to specific cancer types such as acute myeloid leukemia. The protein engages in interactions with other FA pathway proteins like FANCD2 affecting disease progress and therapeutic outcomes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com